• This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. (gc.ca)
  • The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations. (patsnap.com)
  • Teva presented similar arguments and evidence in support of discovery for category 4 and 5 documents (laboratory notes and reports, and protocols or standard operating procedures) relating to development of formulations of tiotropium with different grades or different particle sizes of lactose, during the period from October 1998 to October 2001 regarding the Powder document. (eagar.com.au)
  • The present invention relates to liquid formulations of human growth hormone (hgh, somatropin) which are storage stable, show reduced or no crystallization. (suiseiken.org)
  • Background Single unit dosage forms suitable for oral administration of the active pharmaceutical ingredients are usually formulated in the form of solid formulations. (uni-lj.si)
  • The present Invention relates to the field of pharmaceutical formulation science, In particular wfth respect to methods of improving solubility and bioavailability of lipophilic compounds. (allindianpatents.com)
  • Liquid chromatographic determination of amiodarone hydrochloride and related compounds in raw materials and tablets. (ijpsjournal.com)
  • This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds and related compounds. (trust-meds.com)
  • only the compounds of the substituted azetidinone family among which ezetimibe are the heart of the invention, simvastatin being already known", and "if this association corresponds to the novelty criterion as far as the validity of SPC 05C0040 is concerned, it does not correspond to the additional criterion defined by the CJEU which imposes that the claim relating to the combination discloses the center of the invention. (blogspot.com)
  • The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis. (sumobrain.com)
  • The patent also discloses that (i) the invention had fewer side effects than the first in class drug sildenafil (VIAGRA) due to increased potency, and (ii) could be administered chronically (i.e. daily) rather than "on demand" due to increased half-life. (kluweriplaw.com)
  • The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. (justia.com)
  • These pharmaceutical dosage forms are exclusively rapid-release pharmaceutical compositions. (justia.com)
  • This invention includes pharmaceutical compositions, methods and kits for the treatment or diagnosis of a malignant tumors, including brain tumors, and diseases or disorders characterized by abnormal brain tissue. (patsnap.com)
  • The present invention is furthermore directed to a method of lyophilization using the mannose-containing solution, to pharmaceutical compositions, vaccines, kits, first and second medical uses applying such a mannose-containing solution and/or a nucleic acid (sequence) lyophilized or resuspended with such a solution. (patsnap.com)
  • Solid state forms of Neratinib and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. (lookchem.com)
  • [0001] The present invention relates to the use of erythritol as a stable soluble filler in spray-dried pharmaceutical compositions and, in particular, to novel compositions comprising eythritol as excipient and the NK 3 receptor antagonist talnetant. (patentsencyclopedia.com)
  • The present invention provides systems, methods, and compositions for targeted delivery of nanoparticles and/or agents to tissues, cells, and/or subcellular locales. (patsnap.com)
  • EP 0474 098 relates to the formulation of solid compositions comprising a hardly soluble drug substance co-precipitated with 3 carrfer comprising a water-soluble excipient (PVP) and a blodegradable excipient (polyactic acid). (allindianpatents.com)
  • US 6 027 747 relates to the formulation of solid compositions comprising a hardly soluble drug substance together with a carrier (PVP). (allindianpatents.com)
  • The compositions are made by a process including dissolving the drug in a volatile organic solvent together with a hydrophilic polymer and evaporating the solvent to dryness to form a co-precipitate of the drug with the hydrophilic polymer. (allindianpatents.com)
  • Watanabe T et al relates to the formulation of solid compositions comprising indomethacin and silica. (allindianpatents.com)
  • Although the use of Schedule I substances is generally illegal federally (outside of research), the USPTO has granted numerous patents related to Schedule I drugs. (drugdiscoveryonline.com)
  • The USPTO has issued patents related to cannabis inventions in many areas. (drugdiscoveryonline.com)
  • Prior to the AIA, 102(b) barred patents for inventions that were "on sale in this country, more than one year prior to the date of the application for patent. (venable.com)
  • Upon passage of the AIA, however, the language of 102(b) was changed to bar patents for inventions that were "on sale, or otherwise available to the public before the effective filing date of the claimed invention" (emphasis added). (venable.com)
  • The new "or otherwise available to the public" language raised speculation by some that the on-sale bar for post-AIA patents could only be triggered by sales or offers for sale wherein the details of the commercial transaction, as well as the patented invention itself, were publicly disclosed. (venable.com)
  • As to the three pre-AIA patents, the district court concluded that the invention was not "ready for patenting" prior to the critical date, in view of the fact that a full analysis of the results from the FDA's Phase III clinical trials for Helsinn's 0.25 mg palonosetron formulation were not complete as of the critical date. (venable.com)
  • The patents describe that the claimed preparations have increased stability over known forms of tiotropium-containing inhalable preparations. (eagar.com.au)
  • The invention as claimed in each of the patents addresses the stability issue in inhaled forms of tiotropium. (eagar.com.au)
  • x) In relation to dosage regimen patents, the Court reiterated that there is no blanket prohibition on such patents but that there has been no relaxation of the rules in relevant to the assessment of inventive step for these patents. (kluweriplaw.com)
  • This litigation, relating to the painkiller pregabalin marketed by Warner-Lambert for the treatment of pain under the name Lyrica®, has been keenly followed as the first detailed analysis of infringement of 'second medical use' patents by generically available medicines. (patentdocs.org)
  • An expanded panel of five judges of the Federal Court of Australia has held that two patents owned by AstraZeneca relating to the cholesterol-lowering drug marketed as CRESTOR (active ingredient rosuvastatin) are invalid. (patentology.com.au)
  • The judge at first instance (in Apotex Pty Ltd v AstraZeneca AB (No 4) [2013] FCA 162 ) had found that the AstraZeneca inventions claimed in the patents at issue lacked an inventive step based, in part, on the reasoning of an earlier Full Court panel in Apotex Pty Ltd v Sanofi-Aventis [2009] FCAFC 134 . (patentology.com.au)
  • This dosage form in the form bio-adhesive films with a high bioavailability of the peptide. (rudn.ru)
  • On November 10 2021, a petitioner launched an invalidity attack against the patent at issue, arguing that adjusting the vaccine dosage form, excipients, and other composition in so far as it adapts to different routes of administration is a conventional technical means in this field, which is common knowledge among technical personnel and is devoid of novelty. (managingip.com)
  • Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. (drugs.com)
  • The oral drug preparations provided by the present invention avoid inactivation of the principal ingredient during the process of pharmaceutical manufacturing and display enhanced absorption of the ingredient from the intestinal tract, particularly as a result of the addition of fatty acid(s) to the drug composition. (patenthub.cn)
  • 1. This Practice Notice sets out the practice of the Intellectual Property Office on the way in which inventions concerning a specific medical use of a substance or composition ("second medical use") may be claimed, in the light of the recent EPO Enlarged Board of Appeal decision in G 02/08 ABBOTT RESPIRATORY/Dosage regime . (blogspot.com)
  • The invention relates to the chemical and pharmaceutical industry and concerns capsules with a powder pharmaceutical inhalation composition for the autoimmune diseases treatment. (rudn.ru)
  • With the Helsinn decision, the Federal Circuit clarified that, under the post-AIA version of 102(b), public disclosure of the existence of the sale of a patented item may suffice to invalidate patent under the on-sale bar, even if "the details of the invention" are not "publicly disclosed in the terms of sale. (venable.com)
  • To acquire a patent, the technical details of the invention must be made public via a patent application. (corpbiz.io)
  • The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. (sumobrain.com)
  • In finding the patent obvious, Lord Hodge noted that the starting point was implementing Daugan, which they would do by finding the appropriate dosage regime, having regard to safety, tolerability and effectiveness, via routine and familiar pre-clinical and clinical procedures. (kluweriplaw.com)
  • The online relates an tolerability in surgery transfer and quantitative progression inducer. (siriuspixels.com)
  • Adult dosage ages 1864 years Tadalafil can be used either as needed or taken once a day. (beansandink.com)
  • 4. On 19 February 2010, the EPO Enlarged Board of Appeal issued its decision on G 02/08 ABBOTT RESPIRATORY/Dosage regime . (blogspot.com)
  • Taking AstraZeneca's Australian patent no. 2000023051 (also called 'the 051 patent' or 'the low-dose patent' in the judgment) as an example, the claims are directed to a dosage regime for treating high cholesterol (i.e. 'hypercholesterolemia') with rosuvastatin. (patentology.com.au)
  • The primary judge had essentially addressed the question in the third form, and on the basis that the 'starting point' for devising the claimed dosage regime was the use of rosuvastatin, because that is what she understood to have been the 'problem' addressed by the inventor from a reading of the patent specification. (patentology.com.au)
  • Thus developing the dosage regime was merely a matter of following standard clinical procedures, which could not involve any inventive step. (patentology.com.au)
  • The collegial panel opined that the language attests that claim 1 is not a mere feature of the drug administration method but a feature that would indirectly affect the product's preparation, suggesting that the product is a combination of two dosage forms, namely the injection formulation and the oral formulation, and their respective excipients thereof. (managingip.com)
  • The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. (patsnap.com)
  • The invention relates to a neratinib intermediate crystal as well as a preparation method and application thereof. (lookchem.com)
  • Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. (ijpsjournal.com)
  • The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events. (patsnap.com)
  • Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. (patsnap.com)
  • As to the technical features embodied in claims based on a dosage regimen - such as administration object, method, route, dose, and time interval - the EPO adopts a different approach from the CNIPA. (managingip.com)
  • And U.S. Patent No. 11,154,516 describes a method of treating epileptic-related seizures using CBD. (drugdiscoveryonline.com)
  • The invention relates to the field of pharmaceuticals, in particular to a preparation method of neratinib. (lookchem.com)
  • Validation of a Stability?Indicating HPLC Method for the Determination of Amiodarone HCl and Its Related Substances in Amiodarone HCl Injection. (ijpsjournal.com)
  • Sudden decreased vision, changes in hearing 273, the invention relates to a method for producing medicaments that contain vardenafil hydrochloride. (beansandink.com)
  • The present invention relates to a method of producing a lactose-reduced heat-treated milk-based product which comprises treatment of a milk-based substrate with a lactase and performing a heat treatment. (sumobrain.com)
  • CBD's effects on sleep can vary from person to person, so finding the right dosage and method of consumption that works for you may require some experimentation. (discovermagazine.com)
  • 2008203057 (Capsule Patent) and 757008 (Powder Patent) broadly relate to preparations containing inhalable forms of tiotropium, as either capsules or an inhalable powder. (eagar.com.au)
  • The EPO explicitly recognises the patentability of use claims that are limited to a dosage regimen, whereas the CNIPA is of the opinion that the distinguishing features of an administration process cannot be used to establish novelty in a use claim. (managingip.com)
  • Consequently, it is difficult to patent inventions involving a new dosage regimen in China. (managingip.com)
  • In invalidation decision No. 54827, the CNIPA set forth the reasoning and criteria in assessing novelty regarding product claims incorporating the technical features of a dosage regimen in the field of medicine. (managingip.com)
  • In China, dosage regimen is generally viewed as a feature of drug administration, which, in principle, does not have a limiting effect on the product. (managingip.com)
  • The patent at issue pertains to the improvement of a dosage regimen. (managingip.com)
  • The reason why the CNIPA finds a technical feature of a dosage regimen has a limiting effect could be boiled down to the language employed in drafting the claims. (managingip.com)
  • singularity rather than totality, which has been criticized by other authors, his influence on The history of childcare and children's demystifying abstract natural children is healthcare forms part of the processes of organizing undeniable4. (bvsalud.org)
  • Which ground an objection relates to can often be of importance, in particular since lack of clarity is not a ground for opposition. (jakemp.com)
  • The invention is particularly suitable for once-a-day solid oral pharmaceutical dosage forms in which the active ingredient is memantine, releasing a therapeutically effective amount of the active ingredient over an extended time period. (justia.com)
  • The solid solutions are suitable for being processed into tablets or other solid dosage forms. (allindianpatents.com)
  • The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. (justia.com)
  • T 277/17 (PAR PHARMACEUTICAL) related to a pharmaceutical aqueous solution having a viscosity less than about 1000 cPs. (jakemp.com)
  • When the intermediate crystal form II is used for preparing the neratinib, the dosage of a solvent can be remarkably reduced, the reaction time is shortened, the yield is increased, and meanwhile, the residual quantity of the intermediate A in a final product is remarkably reduced. (lookchem.com)
  • A common feature of the conventional techniques is that the compound is in particulate form, e,g. (allindianpatents.com)
  • Nanoparticles have been combined with hydrogel to form nanoparticle-hydrogel hybrid system as a substitute to conventional dosage forms. (edu.iq)
  • The present invention relates to oral dosage forms containing, as active ingredients, the biologically active proteins, granulocyte colony stimulating factor (G-CSF) and erythropoietin (EPO). (patenthub.cn)
  • To what extent should an ancillary clinical use of the patented invention affect the application of an experimental use exemption? (alrc.gov.au)
  • Sirius Pixels UHDe HEVC Encoder angiotensin-converting online glucose syndrome groups validated on the breast of monomethanesulfonate for induced nodes will implement formed to determine clinical patients comprising the acid of these Notes. (siriuspixels.com)
  • Teva applied to the Court for discovery of documents relating to the development of the invention as claimed. (eagar.com.au)
  • The present invention is directed to pharmaceutical solid, oral dosage forms which exhibit a modified release profile. (justia.com)
  • Adequate sampling should be performed, for example, at 1, 2 and 4 hours and every two hours thereafter until 80% of the drug is released (Guidance for Industry, SUPAC-MR: Modified Release Solid Oral Dosage Forms," Food and Drug Administration, CDER, September 1997, Page 6). (justia.com)
  • Modified release solid oral dosage forms permit the sustained release of the active ingredient over an extended period of time in an effort to maintain therapeutically effective plasma levels over similarly extended time intervals and/or to modify other pharmacokinetic properties of the active ingredient. (justia.com)
  • Immediate release solid dosage forms permit the release of most or all of the active ingredient over a short period of time, such as 60 minutes or less, and make rapid absorption of the drug possible. (justia.com)
  • The specific formulation technique of the present invention relates to stabilised supersaturated solid solutions of lipophilic drugs, such as steroidal molecules and hormones In general. (allindianpatents.com)
  • WO 03/04360 relates to the formulation of solid dispersions comprising a poorly water-soluble drug in combination with a carrier (PVP). (allindianpatents.com)
  • With a broad expertise in the field of solid dosage forms, Dr. Thomas Kipping provides a deep understanding of formulation development and process optimization in the complex area of solubility enhancement. (sigmaaldrich.com)
  • Oral segment dominated the market in 2021 and is expected to continue its dominance over the forecast period owing to the presence of several benefits of oral administration even the sustained & controlled delivery system, ease of administration, easy to formulate solid dosage forms, patient compliance, which are expected to boost the growth of the oral segment in Global Sinusitis Treatment Market during the forecast period. (fatposglobal.com)
  • The Court of Appeal decided that the patent was invalid on the technical ground that 'pain' was not a single disease and so the claim was not adequately supported by the relatively limited data in the patent, relating only to peripheral neuropathic pain. (patentdocs.org)
  • The invention especially relates to a crystal form II of an intermediate A compound 6-amino-4-(3-chloro-4-(pyridine-2-substituted methoxy) aniline)-7-ethoxyquinoline carbonitrile. (lookchem.com)
  • The assessment should not be influenced by the description of the invention provided in the patent specification, or by consideration of any problem that the invention is explicitly or implicitly directed at solving, except to the extent that these are, in fact, part of the prior art or common knowledge in the field. (patentology.com.au)
  • The last measurement should be at a time point where at least 80% of the drug is dissolved (Guidance for Industry, "Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations", Food and Drug Administration, CDER, September 1997, Page 17). (justia.com)
  • It is common knowledge in the art that injection and oral dosage forms usually contain different excipients. (managingip.com)
  • In the present patent embodiment, the combination of injection and oral dosage forms does indeed produce a good immunological effect, and the substantial contribution of the invention is the combination of the injection and oral dosage forms. (managingip.com)
  • As such, oral dosage forms of the present invention can allow for dosage reductions, facilitate accurate dose control, and increase the practical usefulness of the bioactive proteins. (patenthub.cn)
  • La delafloxacine a ete approuvee par la FDA a la dose de 300 mg 2 fois/jour en intraveineux pendant 3 jours suivie d'un relais oral a la dose de 450 mg 2 fois/j dans le traitement des infections compliquees de la peau et des tissus mous, beginner sarms cycle. (theamplace.com)
  • 14. A dosage form as claimed in claim 13 which is for oral administration. (patentsencyclopedia.com)
  • The holder of a patent may prevent potential competitors from infringing the invention claimed, which may convey market exclusivity for up to 20 years from the date the patent application is filed (and sometimes longer if there are patent office or regulatory delays). (drugdiscoveryonline.com)
  • The desired reduction in dosing frequency, for example from administration twice a day to once a day, can be achieved by prolonging the therapeutically effective plasma levels through modified release of active ingredients from dosage forms. (justia.com)
  • By minimizing the peak-trough ratio, i.e. by avoiding high plasma active ingredient concentrations, which are frequently observed after administration of rapid-release pharmaceutical forms, the occurrence of unwanted side effects correlating with the concentration peaks can be reduced. (justia.com)
  • The water that has penetrated in then releases the active ingredient in dissolved or suspended form from one or more orifices in the shell via the osmotic pressure that develops. (justia.com)
  • Diluting tiotropium raises the potential for instability of the substance in the final product formulation, which in turn may give rise to heterogenous dosage and administration of the active substance. (eagar.com.au)
  • The key question addressed by the court in this regard is: what is the appropriate 'starting point' for assessing whether or not a claimed invention involves an inventive step or, conversely, is obvious? (patentology.com.au)
  • Since it is commonly (though not always) possible to regard an invention as providing a solution to a problem, it makes some sense to ask: what was the problem that was solved by the inventor in this case? (patentology.com.au)
  • The invention will help expand the arsenal of controlled-release drugs for the depressive disorders, anxiety and adaptation disorders treatment in human. (rudn.ru)
  • Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. (patsnap.com)
  • Those with severe sleep disorders may require a higher dosage of CBD oil than those with mild conditions. (discovermagazine.com)
  • 5. Subsequent to the decision of the Enlarged Board in G 02/08, only second medical use claims of the form "substance X for use in the treatment of disease Y" will be allowed. (blogspot.com)
  • The invention expanded the arsenal of medicines that provide delivery of the drug to the blood in an unchanged form, for inhalation administration in the autoimmune diseases treatment. (rudn.ru)
  • The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events. (patsnap.com)
  • Global Sinusitis Treatment Market is expected to reach USD 4.7 billion, growing at a CAGR of 4% during forecast period owing to the increasing sinusitis due to the pollution, growing demand for diagnostic tests and treatment, and growing advancements in technology related to sinusitis surgery which are all driving the demand for the growth of the Global Sinusitis Treatment Market. (fatposglobal.com)
  • These advancement in technologies by the key market players is resulting in the invention of new treatment option for various conditions. (fatposglobal.com)
  • 3. Most production of medicines in the Region is limited to compounding and packaging, repacking, and processing bulk medicines into dosage forms using imported raw materials. (who.int)
  • Taking into account various parameters - including the literal interpretation of claim 1, the material contribution of the invention, and the consensus of the parties over the scope of protection of the patent at issue - the CNIPA affirmed that claim 1, in its essence, protects a combination product. (managingip.com)
  • 3. Since then, applicants have been allowed to claim inventions relating to second medical uses using either the new, direct second medical use claim format, the Swiss-type format, or both, pending guidance from the UK courts and/or the EPO Boards of Appeal. (blogspot.com)
  • that applicants may no longer claim second medical use inventions in the Swiss format. (blogspot.com)
  • Proactively applying for patent rights, even where there is no intention to assert them, prevents someone else from seeking to claim the same invention. (drugdiscoveryonline.com)
  • 15. A dosage form as claimed in claim 13 which is a capsule or a tablet. (patentsencyclopedia.com)
  • For example, genetic testing using patented genetic materials or technologies may be conducted on a cohort of individuals primarily to investigate whether a form of genetic test identifies a specific genetic mutation. (alrc.gov.au)
  • Remember that individual responses to CBD can vary, and it may take some time to find the most effective dosage for your specific needs. (discovermagazine.com)
  • Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. (edu.iq)
  • ix) Whether the feature of the claimed invention is an added benefit in which the claimed innovation is obvious for another purpose. (kluweriplaw.com)
  • "In many respects, it's an entrepreneurial space ripe for innovation and invention," ​ says the Washington State Department of Commerce, the state. (outsourcing-pharma.com)
  • The vast majority of pat- Food and Drug Administration (FDA) and of action: Eraxis (anidulafungin) and Zyvox ents related to antibiotics are assigned to phar- other sources. (medpdfarticles.com)
  • Generally, antibiotics are prescribed for bacterial sinusitis involving the sphenoid, frontal, or ethmoid sinuses, due to the chances of facing severe problems related to sinusitis. (fatposglobal.com)
  • The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of RNA and mRNA. (patsnap.com)
  • Accordingly, the USPTO will grant patent protection to applications related to Schedule I drugs, so long as they meet the legal requirements for patentability. (drugdiscoveryonline.com)
  • The content below relates to applications with a complete specification filed before 13 September 2014 . (iponz.govt.nz)
  • Margarethe Richter, Ph.D. is a pharma application specialist at Thermo Fisher Scientific where she develops new applications related to pharmaceutical hot melt extrusion and twin screw granulation. (sigmaaldrich.com)
  • You have filed several international patent applications for packaging and dosage forms of your dietary supplements. (abg-ip.com)
  • The Ministry of Economic Development and Trade of Ukraine developed a (draft Law on Introduction of Amendments to Certain Legislative Acts of Ukraine Regarding the Improvement of Protection of Inventions and Useful Models, called to somehow stem the tide of "patenting" in Ukraine. (attorneys.ua)
  • A modified-release pharmaceutical form should therefore be developed. (justia.com)
  • The problem with this approach is that it makes inventiveness dependent upon how the invention is described in a patent specification, rather than solely by reference to the objective state of the art at the time the invention was made. (patentology.com.au)
  • The goal of this study is to prepare an effective hydrogel form containing prednisolone nanoparticles as a hybrid biomaterial system for transdermal application. (edu.iq)
  • The EPO has developed a large amount of case law which relates specifically to the use of parameters in the claims, in particular whether these claims fulfil the requirements for clarity and sufficiency. (jakemp.com)